SECURITIES AND EXCHANGE COMMISSION
to Section 13 or 15(d) of the Securities Exchange Act of 1934
of report (date of earliest event reported): December 29, 2016
PHARMACEUTICAL RESEARCH CORP.
(Exact Name of Registrant as Specified in its Charter)
File No.: 0-54856
Employer Identification No.)|
Shacham Street. P.O.B. 8324 Petach Tikva, Israel
of Principal Executive Offices)
Telephone Number, including area code: 972 (0) 3-758-2657
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
1.01. Entry Into A Material Definitive Agreement.
December 29, 2016, OWC Pharmaceutical Research Corp. (the “Registrant”), through its wholly-owned Israeli subsidiary,
One World Cannabis Ltd. (‘OWC”), entered into a Research Agreement with Medical Research Infrastructure Development
and Health Services Fund by Chaim Sheba Medical Center, a non-profit organization incorporated under the laws of the State of
Israel (the “Fund”), a copy of which Research Agreement is attached as Exhibit 10.21. hereto.
to the Research Agreement, the Fund shall perform a Phase I, double blind, randomized, placebo-controlled, maximal dose study
(the “Study”) to determine the safety, tolerability of topical cream containing MGC (“Medical Grade Cannabis”
or the “Study Drug”) in healthy volunteers, employing the services of Dr. Aviv Barzilay, Director of the Department
of Dermatology- Chaim Sheba Medical Center, Tel Hashomer, Israel, to lead the Study (the “Investigator”). The Study
shall be conducted in compliance with the following, as defined in the Research Agreement: (1) the Protocol; (2) the Ministry
Guidelines; (3) the instructions and terms specified in the Helsinki Committee’s approval; (4) the ICH-GCP; (5) the Helsinki
Declarations; (6) the applicable laws, rules and regulations regulating such studies which are applicable in Israel (the “Applicable
Laws”); and (7) written instructions and prescriptions issued by the OWC and governing the administration of the Study Drug.
undertakes to pay the Fund the amounts specified in the payment schedule set forth in the Research Agreement.
9.01 Financial Statements and Exhibits.
The following documents are filed as exhibits to this report on Form 8-K or incorporated by reference herein. Any document incorporated
by reference is identified by a parenthetical reference to the SEC filing that included such document.
Agreement between One World Cannabis Ltd and Medical Research Infrastructure Development and Health Services Fund by Chaim
Sheba Medical Center dated December 29, 2016, filed herewith.|
Pharmaceutical Research Corp.|
January 12, 2017